Clinical Trial Update: Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subacute Cutaneous Lupus Erythematosus

Drugs mentioned

• KRP203 (KRP-203)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Subacute Cutaneous Lupus Erythematosus | Phase 2 | Status: COMPLETED